PDGF receptor kinase inhibitors for the treatment of restenosis

被引：75
|
作者：
Levitzki, A [1 ]
机构：
[1] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel
来源：
CARDIOVASCULAR RESEARCH | 2005年 / 65卷 / 03期
关键词：
PDGF; tyrphostins; restenosis; cancer;
D O I：
10.1016/j.cardiores.2004.08.008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The clogging of arteries by neointima is a hallmark of atherosclerosis and of restenosis following balloon angioplasty. The realization in the 1980s that PDGF and its receptor play a key role in the onset of neointimal formation led us to develop PDGFR kinase inhibitors as antirestenosis agents. In this review, we describe the development of these inhibitors and their implementation as antirestenosis agents by localized delivery to the site of injury. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
下载
收藏
页码：581 / 586
页数：6
相关论文
共 50 条
  • [21] Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors
    Feng, Shu
    Shao, Longjiang
    Castro, Patricia
    Coleman, Ilsa
    Nelson, Peter S.
    Smith, Paul D.
    Davies, Barry R.
    Ittmann, Michael
    ONCOTARGET, 2017, 8 (04) : 6179 - 6192
  • [22] Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
    Pallis, A. G.
    Syrigos, K. N.
    LUNG CANCER, 2013, 80 (02) : 120 - 130
  • [23] Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
    Roskoski, Robert, Jr.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 356 (02) : 323 - 328
  • [24] PDGF-α and PDGF-β are expressed in endometrial stromal sarcoma:: a potential therapeutic target for tyrosine kinase inhibitors?
    Liegl, B.
    Reich, O.
    Nogales, F. F.
    Regauer, S.
    HISTOPATHOLOGY, 2006, 49 (05)
  • [25] PDGF receptor desensitization by G protein-coupled receptor kinase-2
    Murray, JP
    Peppel, K
    Freedman, NJ
    CIRCULATION, 2000, 102 (18) : 274 - 274
  • [26] STRUCTURE-ACTIVITY STUDIES OF PHOSPHORYLATED PEPTIDE INHIBITORS OF THE ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH PDGF-BETA RECEPTOR
    RAMALINGAM, K
    EATON, SR
    CODY, WL
    LU, GH
    PANEK, RL
    WAITE, LA
    DECKER, SJ
    KEISER, JA
    DOHERTY, AM
    BIOORGANIC & MEDICINAL CHEMISTRY, 1995, 3 (09) : 1263 - 1272
  • [27] Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer
    Masiello, David
    Mohi, M. Golam
    McKnight, Nicole C.
    Smith, Bradley
    Neel, Ben G.
    Balk, Steven P.
    Bubley, Glenn J.
    CANCER BIOLOGY & THERAPY, 2007, 6 (02) : 195 - 201
  • [28] Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
    Hackett, John
    Xiao, Zili
    Zang, Xiao-Ping
    Lerner, Megan L.
    Brackett, Daniel J.
    Brueggemeier, Robert W.
    Li, Pui-Kai
    Pento, J. Thomas
    ANTICANCER RESEARCH, 2007, 27 (6B) : 3801 - 3806
  • [29] Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
    Bellantoni, Andrew J.
    Wagner, Lars M.
    CANCERS, 2021, 13 (14)
  • [30] Receptor tyrosine kinase inhibitors in cancer
    Ebrahimi, Nasim
    Fardi, Elmira
    Ghaderi, Hajarossadat
    Palizdar, Sahar
    Khorram, Roya
    Vafadar, Reza
    Ghanaatian, Masoud
    Rezaei-Tazangi, Fatemeh
    Baziyar, Payam
    Ahmadi, Amirhossein
    Hamblin, Michael R.
    Aref, Amir Reza
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (04)
12345